Single Cell Technology (SCT) and AB Biosciences (ABB) have entered into a collaboration to identify new therapeutic antibodies.
Under the deal, SCT will use its patented platform to screen plasma cells, measure the kinetics of secreted antibodies and sequence the cognate light and heavy chain mRNA powered by Next Generation Sequencing (NGS).
The deal will see ABB select antibody targets, engineer protein antigens and develop analytical tools to further characterize the large panel of antibodies identified by SCT's platform.
The collaboration is claimed to fundamentally change the paradigm for antibody development by bringing together the latest technological innovations with refined protein engineering and assay development.
SCT founder and CEO Chun-Nan Chen said the company has developed a new antibody discovery platform.
"Together with AB Biosciences' premier protein engineering capacity and astute insights in antibody drug development, we will utilize our platform to outperform traditional antibody discovery techniques," Chen said.
ABB founder and CEO Yen-Ming Hsu said, "ABB's extensive knowledge in target selection for antibody drugs, and expertise in engineering, production, and assay development of high quality target-related proteins are fully complementary to SCT's innovations in rapid identification and characterization of therapeutic antibodies."
